Core Viewpoint - Hangzhou Deshi Biotechnology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, marking a significant step in its journey towards going public after receiving regulatory approval [1][2]. Group 1: Company Overview - Deshi Biotechnology focuses on chromosome karyotype analysis, a classic method for diagnosing major diseases related to chromosomal abnormalities, which include birth defects, infertility, and hematological malignancies [1]. - The traditional karyotype analysis method relies heavily on manual operations, resulting in an average accuracy rate of only about 50% and a reporting cycle of approximately 30 days [1]. Group 2: Market Position and Innovation - The automated karyotype analysis market is dominated by international giants like Carl Zeiss and Leica, which hold over 95% of the market share [2]. - In response to the significant market demand and the lack of domestic equipment, Deshi Biotechnology has pursued an independent innovation path, developing intelligent devices and systems based on the iMedImage platform model [2]. - The company has created a highly integrated automated cell laboratory pipeline that covers four key stages of chromosome karyotype analysis: cell harvesting, slide preparation, image acquisition, and intelligent analysis, achieving full-process automation and standardization [2]. - By 2024, Deshi Biotechnology is projected to capture a market share of 30.6% in China's chromosome karyotype analysis sector, surpassing international competitors and marking a leap forward for domestic manufacturers [2].

Core Viewpoint - The company, Deshi Biotechnology, has submitted a second listing application to the Hong Kong Stock Exchange, marking a significant step in its journey towards going public after receiving regulatory approval [1][10]. Group 1: Company Overview - Deshi Biotechnology is recognized as a "national specialized and innovative small giant" in the field of chromosome karyotype analysis, achieving the highest market share in China [1][7]. - The company has developed a fully automated cell laboratory workflow that significantly enhances the accuracy of chromosome karyotype analysis to over 99%, addressing long-standing clinical challenges in the industry [3][6]. Group 2: Industry Context - Chromosome karyotype analysis is crucial for diagnosing various genetic disorders, including Down syndrome and certain blood cancers, but has historically faced issues with accuracy and lengthy reporting times [2]. - The market for chromosome karyotype analysis has been dominated by international giants like Carl Zeiss and Leica, which hold over 95% of the market share [3]. Group 3: Financial Performance - In 2024, Deshi Biotechnology achieved a market share of 30.6% in the chromosome karyotype analysis sector, surpassing international competitors [7]. - The company's revenue for the first three quarters of 2025 reached 112 million RMB, a 470% increase compared to 19.59 million RMB in the same period of 2024, with a gross margin of 75.9% [7][8]. - As of September 30, 2025, the company had cash and cash equivalents totaling 250 million RMB, indicating strong market recognition and the ability to convert technological advantages into commercial success [7].